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Functional parts of the 
system of Haemostasis
Blood vessels
Platelet
Factors of coagulation
Fibrinolytic system
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INTRISIC PATHWAY  And  EXTRINSIC PATHWAY
Of The  HAEMOSTASIS
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FIBRINOLYTIC SYSTEM
* sistem na fibrinoliza
THREE DIFFERENT PATHWAYS of ACTIVATION:
A: extrinsic pathway
V: intrisic pathway dependent of f. XII
S: intrisic pathway undependent of f. XII
A V S
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Thrombosis is the formation, from the
components of blood, of an abnormal mass
within the vascular system.
It involves the interaction of:
vascular,
cellular, and
humoral factors within a flowing stream
of blood.
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Thrombosis and the
complicating emboli that can
result are among the most
important causes of sickness
and death in developed
countries.
Thrombosis is of greater overall 
clinical importance in terms of 
morbidity and mortality than all of 
the hemorrhagic disorders combined. 
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Excessive activation of coagulation or 
inhibition of anticoagulant mechanisms may 
result in hypercoagulability and thrombosis. 
Injury to the vessel wall, alterations 
in blood flow, and changes in the composition 
of blood are major factors leading to 
thrombosis.
Thrombotic disorders can be caused by: 
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Most of these disorders have also been 
reported as acquired conditions.
- an inherited deficiency of antithrombin III, 
- heparin cofactor II,
- protein C,
- protein S, 
- thrombomodulin, 
- plasminogen, or tissue plasminogen 
activator; 
- an activated protein C resistance (factor V 
Leiden); 
- dysfibrinogenemia; and
- homocysteinemia. 
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 Anticoagulant drugs
ANTITHROMBOTIC AGENTS
Antiplatelet Agents
Anticoagulant  Drugs
Thrombolytic Agents
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 The evidence from clinical trials and
focused reviews supports continuing oral
anticoagulation for patients needing
dentoalveolar surgery.
 As long as the INR is within the
therapeutic range and local hemostatic
measures are taken following the surgery,
these patients will have little chance of
developing uncontrolled bleeding following
the surgery.
CONCLUSION
 Local hemostasis will control the
bleeding in the few patients who
develop postsurgical bleeding.
 The risk of uncontrolled life
threatening bleeding following
dentoalveolar surgery is so low that
it is not necessary to stop
anticoagulation even for a short
interval and risk thromboembolism in
patients on oral anticoagulants.
CONCLUSION
